Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2024 Apr 23;8(8):2018-2019.
doi: 10.1182/bloodadvances.2024012569.

Survival for the fittest: guadecitabine in rel/ref AML

Joshua Sheehy  1   2   3 , Steven W Lane  1   2   3
Affiliations
Comment

Survival for the fittest: guadecitabine in rel/ref AML

Joshua Sheehy et al. Blood Adv. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: S.W.L. has received consulting fees from AbbVie (venetoclax) and research funding from Bristol Myers Squibb (azacitidine). J.S. declared no competing financial interests.

Figures

None
Guadecitabine vs treatment choice in patients with relapsed or refractory AML demonstrates higher response rates and favourable survival outcomes in certain subgroups. This is at the expense of higher toxicity (neutropenia).
See this image and copyright information in PMC

Comment on

References

    1. Roboz GJ, Sanz G, Griffiths E, et al. Guadecitabine vs TC in relapsed/refractory AML after intensive chemotherapy: randomized phase 3 ASTRAL-2 trial. Blood Adv. 2024;8(8):2020–2029. - PubMed
    1. Totiger TM, Ghoshal A, Zabroski J, et al. Targeted therapy development in acute myeloid leukemia. Biomedicines. 2023;11(2) - PMC - PubMed
    1. Stomper J, Rotondo JC, Greve G, Lübbert M. Hypomethylating agents (HMA) for the treatment of acute myeloid leukemia and myelodysplastic syndromes: mechanisms of resistance and novel HMA-based therapies. Leukemia. 2021;35(7):1873–1889. - PMC - PubMed
    1. Fenaux P, Gobbi M, Kropf PL, et al. Guadecitabine vs treatment choice in newly diagnosed acute myeloid leukemia: a global phase 3 randomized study. Blood Adv. 2023;7(17):5027–5037. - PMC - PubMed
    1. DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383(7):617–629. - PubMed

Publication types